Literature DB >> 31136203

Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.

Garvey Liu1, Vidhi Khanna1, Ameya Kirtane1, Alex Grill1, Jayanth Panyam1.   

Abstract

Oral consumption of curcumin, a natural polyphenol, is associated with reduced incidence of cancer. Yet, a significant amount of the orally dosed compound is eliminated in the feces, and a major fraction of the absorbed compound is metabolized to inactive glucuronides, resulting in poor bioavailability (<1%). It is not known how oral curcumin exhibits chemopreventive activity. We propose curcumin glucuronide is an inflammation-responsive natural prodrug that is converted back to curcumin on demand at the site of action. Our studies show elevated levels of β-glucuronidase, an enzyme that hydrolyzes the glycosidic bond of glucuronides to generate the parent compound, in human breast cancer. Oral administration of curcumin in mouse tumor models generated significant tumor levels of the polyphenol. Intravenous administration of the glucuronide resulted in the formation of curcumin in the tumor tissue. Chronic daily oral curcumin dosing led to tumor accumulation of curcumin and inhibition of tumor growth in tumor models with high β-glucuronidase activity. Overall, the study presented here provides preliminary evidence for a novel mechanism of action for orally administered curcumin.-Liu, G., Khanna, V., Kirtane, A., Grill, A., Panyam, J. Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.

Entities:  

Keywords:  cancer prevention; curcumin glucuronide; β-glucuronidase

Mesh:

Substances:

Year:  2019        PMID: 31136203      PMCID: PMC9272759          DOI: 10.1096/fj.201900166R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  44 in total

1.  Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.

Authors:  T E Mürdter; B Sperker; K T Kivistö; M McClellan; P Fritz; G Friedel; A Linder; K Bosslet; H Toomes; R Dierkesmann; H K Kroemer
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

2.  Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.

Authors:  Lan Li; Fadi S Braiteh; Razelle Kurzrock
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

3.  Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin.

Authors:  Alex E Grill; Brenda Koniar; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

4.  Curcumin glucuronides: assessing the proliferative activity against human cell lines.

Authors:  Ashutosh Pal; Bokyung Sung; Basvoju A Bhanu Prasad; Paul T Schuber; Sahdeo Prasad; Bharat B Aggarwal; William G Bornmann
Journal:  Bioorg Med Chem       Date:  2013-11-12       Impact factor: 3.641

5.  Phase II trial of curcumin in patients with advanced pancreatic cancer.

Authors:  Navneet Dhillon; Bharat B Aggarwal; Robert A Newman; Robert A Wolff; Ajaikumar B Kunnumakkara; James L Abbruzzese; Chaan S Ng; Vladimir Badmaev; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

6.  Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity.

Authors:  Ting-Yi Juan; Steve R Roffler; Hsien-San Hou; Shih-Ming Huang; Kai-Chuan Chen; Yu-Lin Leu; Zeljko M Prijovich; Cheng-Ping Yu; Chang-Chieh Wu; Guang-Huan Sun; Tai-Lung Cha
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

7.  Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells.

Authors:  Nicole Sabolovic; Anne-Claude Humbert; Anna Radominska-Pandya; Jacques Magdalou
Journal:  Biopharm Drug Dispos       Date:  2006-05       Impact factor: 1.627

8.  Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents.

Authors:  Guang Liang; Lili Shao; Yi Wang; Chengguang Zhao; Yanhui Chu; Jian Xiao; Yu Zhao; Xiaokun Li; Shulin Yang
Journal:  Bioorg Med Chem       Date:  2008-11-01       Impact factor: 3.641

9.  A comprehensive analysis of breast cancer microbiota and host gene expression.

Authors:  Kevin J Thompson; James N Ingle; Xiaojia Tang; Nicholas Chia; Patricio R Jeraldo; Marina R Walther-Antonio; Karunya K Kandimalla; Stephen Johnson; Janet Z Yao; Sean C Harrington; Vera J Suman; Liewei Wang; Richard L Weinshilboum; Judy C Boughey; Jean-Pierre Kocher; Heidi Nelson; Matthew P Goetz; Krishna R Kalari
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more
  3 in total

1.  Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.

Authors:  Garvey Liu; Vidhi Khanna; Ameya Kirtane; Alex Grill; Jayanth Panyam
Journal:  FASEB J       Date:  2019-05-28       Impact factor: 5.834

2.  Comparing the immunogenicity of glycosidase-directed resiquimod prodrugs mediated by cancer cell metabolism.

Authors:  Austin T Ryan; Anunay J Pulukuri; Maryam Davaritouchaee; Armina Abbasi; Aaron T Hendricksen; Larissa K Opp; Anthony J Burt; Amy E Nielsen; Rock J Mancini
Journal:  Acta Pharmacol Sin       Date:  2020-05-25       Impact factor: 6.150

Review 3.  Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives.

Authors:  María Ángeles Ávila-Gálvez; Juan Antonio Giménez-Bastida; Juan Carlos Espín; Antonio González-Sarrías
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.